Gene Tweaking Boosts Spliceostatin Synthesis | Chemical & Engineering News
Volume 94 Issue 1 | p. 21 | Concentrates
Issue Date: January 4, 2016

Gene Tweaking Boosts Spliceostatin Synthesis

Biosynthetic Engineering: Pfizer team reprograms engineered bacterium to increase yield of promising anticancer natural product
Department: Science & Technology
News Channels: Biological SCENE, Organic SCENE
Keywords: spliceostatin, thailanstatin, cancer drug, synthetic biology

Pfizer scientists have reprogrammed an engineered microbe to improve the fermentation yield of the promising cancer drug thailanstatin A, a crucial step in its further development as a chemotherapy agent (Metab. Eng. 2015, DOI: 10.1016/j.ymben.2015.11.003). Thailanstatin A is a member of the spliceostatin family of bacterial natural products that interact with the spliceosome, the protein-RNA hybrid complex that is responsible for editing mRNA before the ribosome uses it to make proteins. Misregulation of mRNA splicing and mutations in the splicing machinery are associated with several cancers, and spliceostatins can put a halt to the problems. Alessandra S. Eustáquio and colleagues previously developed a biosynthetic pathway to make more potent and stable spliceostatins, but it was limited to producing 60 mg/L of thailanstatin A. The team found a bottleneck in the pathway, which they alleviated by increasing the expression of a gene to improve selective formation of a key hydroxyl group. The reprogramming helped increase production to 2.5 g/L, a level sufficient to support clinical trials.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment